Jupiter Lend has overtaken Kamino as the top lending market on Solana, reaching about $1.411 billion in total value locked (TVL) compared to Kamino's $1.403 billion. Jupiter also leads in active loans with $1.043 billion versus Kamino's $1.007 billion, driven by a 28.1% TVL growth in the past 30 days. Despite this, Kamino still generates higher fees and revenue, showing better capital monetization. Jupiter's growth was fueled by the August launch of Jupiter Lend v2, which introduced innovative features like Smart Collateral and Smart Debt, enhancing user returns and loan management. This shift reflects the broader boom in Solana's DeFi activity, with trading volumes surpassing major stock exchanges. The competition between Jupiter and Kamino will continue as both platforms vie for dominance in a rapidly expanding market.
Jupiter Lend and Kamino Lend's competition in Solana lending is the subject, with Pluang's market snapshot showing a mixed day among 50 major cryptocurrencies as of Oct 07, 2026 00:03 WIB: 24 rose and 25 fell. Filecoin (FIL) gained 6.64% to Rp20.810 with more selling than buying at 56% Sell / 44% Buy, Avalanche (AVAX) rose 5.17% to Rp204.576 with a stronger buy interest at 65% Buy, and Theta Network (THETA) dropped 100% Sell activity despite a 4.22% price increase to Rp4.277. This contrast highlights varied investor behavior across assets on the platform.
Stryker experienced an 8.8% stock drop on September 8, 2026, wiping out over $10 billion in market value due to ongoing manufacturing problems that were thought resolved. Truist Financial lowered its price target from $340 to $310, reflecting concern...
Bank OZK is scheduled to release its Q3 2026 earnings after market close on October 20, providing investors with updated financial results to compare against Citigroup's current Sell rating. The bank's latest balance sheet shows $41.70 billion in tot...
Scotiabank has increased its price target for Pfizer stock from $30.00 to $33.00, suggesting a potential upside of 20.9% from the current trading price of $27.31. Pfizer, a major pharmaceutical company, holds a strong buy rating with a Zacks Rank of ...
Citigroup has raised its price target for AstraZeneca to £186.00 from £178.00, maintaining a Buy rating following successful Phase 3 clinical trials. The increase reflects higher peak sales forecasts for drugs tozorakimab and SERENA-6, offsetting the...
An analyst from BMO Capital set a $67 price target for Devon Energy, suggesting a 40% upside from its current share price of around $48. The oil and gas producer has consistently beaten earnings estimates recently, showing strong financial health. Ho...
